Endocrine therapy using the progesterone receptor (PR) antagonist RU486 prevents the development of mammary tumors and induces the regression of lymph node and lung metastases in mouse breast cancer models [32], [33], supporting a role for PR in these processes. Here, PGR is linked to breast carcinoma.